Neurons in the adult spinal cord have the potential to regenerate. Axon growth is blocked by inhibitors.
Cethrin is a biologic drug in development to treat SCI

- Cethrin is a first-in-class drug; an enzyme that inactivates Rho
- Cethrin is delivered during surgery
- The mechanism of action is understood
  - Regeneration
  - Neuroprotection
  - Decrease invasion of monocytes
- A single application has durable action

Phase I/IIa Multi-center Clinical Trial
Promising clinical results

Motor scores in patients with cervical injury

Cervical conversion rates:
31% Cethrin VS 10% expected
Next steps in the development of Cethrin

**Acute Spinal Cord Injury**
- Drug development and clinical plan
- Carry out Phase 2 b study

**Chronic Spinal Cord Injury**
- Collaboration with Dr. Wise Young (Rutgers) to combine Cethrin with umbilical cord blood cell therapy.
- Pre-clinical proof-of-concept
- IND and clinical study

---

Cures for SCI are achievable

- **Not-for-profit**
  - Basic Research
  - Preclinical efficacy

- **CMC**
  - Drug manufacture & scale-up
  - GMP drug

- **Safety**
  - Safety/toxicology
  - Pharmacokinetics

- **Clinical Trials**
  - Investigation of New Drug (IND)
  - Clinical Study

---

**Biotech**

- **Cervical**
- **Thoracic**
- **Lumbar**
- **Sacral**
Working together will accelerate development of cures for SCI.